Trial ID or NCT#



not recruiting iconNOT RECRUITING


The primary objective of this study is to evaluate the effect of presatovir on respiratory syncytial virus (RSV) viral load in autologous or allogeneic hematopoietic cell transplant (HCT) recipients with an acute RSV upper respiratory tract infection (URTI), the effect of presatovir on development of lower respiratory tract complication, being free of any supplemental oxygen progression to respiratory failure, and pharmacokinetics (PK), safety, and tolerability of presatovir.

Official Title

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract

Eligibility Criteria

Ages Eligible for Study: 18 Years to 75 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Dora Ho
Dora Ho
Infectious disease doctor
Clinical Associate Professor, Medicine - Infectious Diseases
Anne Liu
Anne Liu
Allergist, Immunologist, Infectious disease doctor, Ear, nose, and throat specialist
Clinical Associate Professor, Pediatrics - Immunology and Allergy Clinical Associate Professor, Medicine - Infectious Diseases
Aruna Subramanian
Aruna Subramanian
Infectious disease doctor
Clinical Professor, Medicine - Infectious Diseases

Contact us to find out if this trial is right for you.


(650) 498-7061